Tag: Metastatic CRC options

Home / Metastatic CRC options

Categories

Fruquintinib is approved by the USFDA in refractory metastatic colorectal cancer

The Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) on November 8, 2023, for adult patients with metastatic colorectal cancer (mCRC) who have undergone sp...
metastatic-crc-options

Scan the code